The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia.
Here are the top 5 CURE stories for June 2019.
From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.
The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
In a talk about her new book, Vanessa Bayer explains how leukemia contributed to her comic perspective and sense of empathy.
Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.
After treatment, this survivor was terrified of everyone and everything until her very wise doctor said, “I did not put you through all this for you to put yourself in a bubble – go live your life.” And she has… for 16 years and counting.
This essay nominating Wilafe Tolentino, B.S.N., RN, OCN for CURE®'s Extraordinary Healer® Award was written by Dr. Fred Hardwicke, M.D., of the University Medical Center Southwest Cancer Center, Lubbock, Texas.
The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.
From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.
The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.
Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.
The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.
An extraordinary group of nurses, led by nurse manager Taylor Andrews, B.S., RN, BMTCN, have made it their mission to become fairy godmothers for the patients they care for in the bone marrow transplant unit and to make their wishes come true.
